Herrmann Wolfram J, Weikert Cornelia, Bergmann Manuela, Boeing Heiner, Katzke Verena A, Kaaks Rudolf, Tiller Daniel, Greiser Karin Halina, Heier Margit, Meisinger Christa, Schmidt Carsten Oliver, Neuhauser Hannelore, Heidemann Christin, Jünger Claus, Wild Philipp S, Schramm Sara Helena, Jöckel Karl-Heinz, Dörr Marcus, Pischon Tobias
Forschergruppe Molekulare Epidemiologie, Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (MDC), Robert-Rössle-Straße 10, 13125, Berlin, Deutschland.
Charité - Universitätsmedizin Berlin, Berlin, Deutschland.
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2018 Apr;61(4):420-431. doi: 10.1007/s00103-018-2712-4.
Cardiovascular and metabolic diseases are a major cause of mortality and loss of quality of life in Germany. Research into risk factors of these diseases requires large population-based cohort studies. Complete and accurate assessment of the incidence of cardiovascular and metabolic diseases is a key element for valid interpretation of the results from such studies.
Our aim was to identify population-based cohort studies with incidence of cardiovascular and metabolic diseases in Germany and to summarize their methods for assessment and classification of disease endpoints, including myocardial infarction, type 2 diabetes, stroke, heart failure, and arterial hypertension.
Within the framework of a workshop, representatives of the ascertained population-based cohort studies in Germany with incidence of cardiovascular or metabolic diseases were invited to present and to systematically provide information on their methods of endpoint identification.
We identified eight studies from different regions in Germany with a total of 100,571 participants, aged 18-83 years at baseline. Self-reporting by study participants is the major source for further inquiries to assess disease endpoints in these studies. Most studies use additional data sources to verify the incidence of diseases, such as documents provided by the treating physician or hospital.
Our results highlight the central role of self-reporting and the efforts associated with identification and verification of disease endpoints in cohort studies. They also provide a basis for future population-based studies that aim for standardized assessment of the incidence of cardiovascular and metabolic diseases.
心血管疾病和代谢性疾病是德国死亡和生活质量下降的主要原因。对这些疾病的危险因素进行研究需要开展大规模的基于人群的队列研究。全面、准确地评估心血管疾病和代谢性疾病的发病率是有效解读此类研究结果的关键因素。
我们的目的是确定德国基于人群的、包含心血管疾病和代谢性疾病发病率的队列研究，并总结其疾病终点评估和分类方法，这些疾病终点包括心肌梗死、2型糖尿病、中风、心力衰竭和动脉高血压。
在一个研讨会的框架内，邀请了德国已确定的、包含心血管疾病或代谢性疾病发病率的基于人群的队列研究的代表，来介绍并系统提供其终点识别方法的信息。
我们从德国不同地区确定了8项研究，共有100571名参与者，基线年龄为18至83岁。研究参与者的自我报告是这些研究中进一步询问以评估疾病终点的主要来源。大多数研究使用其他数据源来核实疾病的发病率，如治疗医生或医院提供的文件。
我们的结果突出了自我报告的核心作用以及队列研究中疾病终点识别和核实所涉及的工作。它们还为未来旨在对心血管疾病和代谢性疾病发病率进行标准化评估的基于人群的研究提供了基础。
